Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms is a research paper published in British Journal of Haematology (2023). On theSindex it has a DataRank of 0. It has been cited 22 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
American Society of Hematology
Grant: Fellow Scholar Award in Basic/Translational Resear
National Institutes of Health
Grant: K08 CA218901
National Institutes of Health
Grant: P30 CA08748
National Institutes of Health
Grant: P50 CA254838‐01
National Institutes of Health
Grant: R01 CA242020
National Institutes of Health
Grant: R01 CA251138
National Institutes of Health
Grant: R37CA259260
National Institutes of Health
Grant: U24 CA264369‐01A1
National Center for Advancing Translational Sciences
Grant: 2KL2‐TR‐2385
National Heart, Lung, and Blood Institute
Grant: R01 HL128239
NCATS NIH HHS
Grant: KL2 TR002385
NCI NIH HHS
Grant: L30 CA231804
NCI NIH HHS
Grant: U24 CA264369
NCI NIH HHS
Grant: P50 CA254838
NCI NIH HHS
Grant: P30 CA008748
Prevent Cancer Foundation
Edward P. Evans Foundation
Leukemia and Lymphoma Society
Melanoma Research Alliance
Cycle for Survival
MeSH Terms
Keywords